Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Visit

ESH CML 2022 | The importance of better selecting patients with CML who are eligible for treatment discontinuation

Susanne Saussele • 22 Oct 2022

ESH CML 2022

Chronic Myeloid Leukemia Leukemia

Susanne Saussele, MD, University of Heidelberg, Mannheim, Germany, emphasizes the importance of better defining criteria for patient selection for treatment discontinuation in chronic myeloid leukemia (CML) to improve treatment-free remission (TFR) success and quality of life (QoL). This interview took place at the 24th Annual John Goldman Conference on Chronic Myeloid Leukemia (ESH CML) held in Mandelieu-La Napoule, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

BMS, Incyte, Novartis, Honoraria: BMS, Incyte, Novartis, Pfizer, Roche

The impact of ACA in CML & the importance of monitoring these patients

Susanne Saussele • 22 Oct 2022

Examples of challenging scenarios for TFR in CML & how to manage them

Susanne Saussele • 22 Oct 2022

Antibody responses to COVID-19 vaccines in patients with hematological malignancies

Susanne Saussele • 11 Dec 2021

Vaccination efficacy in patients with hematological malignancies

Susanne Saussele • 11 Dec 2021

Related Videos

The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial

Felicitas Thol • 19 Apr 2024

Integrating genomics and MRD in transplant decision-making for patients with AML

Jurjen Versluis • 22 Apr 2024

Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL

Alberto Olaya-Vargas • 15 Apr 2024

Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS

Sridhar Chaganti • 16 Apr 2024